Transversus Abdominis Plane Block For Renal Transplant Recipients
NCT00905957 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52
Last updated 2022-06-03
Summary
The purpose of this study is to evaluate the efficacy of a local anaesthetic injection in the plane between the abdominal muscles in reducing the amount of pain relief required after surgery.
Conditions
- Disorder Related to Renal Transplantation
- Pain
Interventions
- PROCEDURE
-
TAP block
TAP block using 20 ml of a local anaesthetic agent will be used in the treatment group
- PROCEDURE
-
TAP block with placebo
TAP block using a placebo after induction of anaesthesia
Sponsors & Collaborators
-
Liverpool University Hospitals NHS Foundation Trust
lead OTHER_GOV
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-10-31
- Primary Completion
- 2011-06-30
- Completion
- 2011-06-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain
NCT00449176 ·Status: COMPLETED ·Phase: PHASE3
-
Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain
NCT00594516 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)
NCT01631513 ·Status: WITHDRAWN ·Phase: PHASE4
-
A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet
NCT01273532 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine
NCT00505414 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis
NCT00745069 ·Status: COMPLETED ·Phase: PHASE2
-
Tapentadol (CG5503)
NCT00421928 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine
NCT00472303 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety
NCT00364533 ·Status: TERMINATED ·Phase: PHASE3
-
Preemptive Tapentadol on Post-operative Analgesia Following Total Knee Arthroplasty
NCT03351517 ·Status: COMPLETED ·Phase: NA
-
Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations (Protocol ID: 855509)
NCT00469053 ·Status: TERMINATED ·Phase: PHASE1
-
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain
NCT00487435 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects
NCT02019485 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
NCT00983385 ·Status: COMPLETED ·Phase: PHASE3
-
Tapentadol in Chronic Malignant Tumour Related Pain
NCT01264887 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic
NCT00983073 ·Status: COMPLETED ·Phase: PHASE3
-
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain
NCT00986180 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain
NCT00364546 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans
NCT01500317 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery
NCT00361582 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain
NCT02151682 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants
NCT01981278 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease
NCT00784277 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants
NCT00805142 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.
NCT00982280 ·Status: TERMINATED ·Phase: PHASE3